Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Antiviral Agents

Lack of Emergence of Cytomegalovirus UL97 Mutations Conferring Ganciclovir (GCV) Resistance following Preemptive GCV Therapy in Allogeneic Stem Cell Transplant Recipients

C. Gilbert, J. Roy, R. Belanger, R. Delage, C. Beliveau, C. Demers, G. Boivin
C. Gilbert
Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Department of Medical Biology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Roy
Bone Marrow Transplant Unit, Maisonneuve-Rosemont Hospital, and Department of Medicine, Université de Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Belanger
Bone Marrow Transplant Unit, Maisonneuve-Rosemont Hospital, and Department of Medicine, Université de Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Delage
Bone Marrow Transplant Unit, St.-Sacrement Hospital and Department of Medicine, Université Laval, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Beliveau
Department of Microbiology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Demers
Bone Marrow Transplant Unit, St.-Sacrement Hospital and Department of Medicine, Université Laval, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Boivin
Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Department of Medical Biology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.45.12.3669-3671.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Fifty allogeneic stem cell transplant recipients were enrolled in a prospective cytomegalovirus pp65 antigenemia-guided preemptive therapy trial. Among these, 10 of 34 patients who received ganciclovir exhibited sustained and/or recurrent antigenemia despite treatment. Thirteen leukocyte preparations from these 10 subjects were screened for the presence of the most frequent cytomegalovirus UL97 mutations conferring ganciclovir resistance. None of these mutations were detected after mean and median ganciclovir exposures of 31.6 and 28.0 days, respectively.

Cytomegalovirus (CMV) infections represent a serious threat in patients undergoing allogeneic bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT) (15). In order to reduce the morbidity and mortality associated with CMV disease, most centers have now adopted one of the two following preventive strategies. The first approach, referred to as universal prophylaxis, is based on the administration of a potent anti-CMV drug, usually ganciclovir (GCV), to all patients for the first 3 months after transplantation. Prophylaxis with GCV has been reported to be highly effective in reducing the occurrence of early CMV disease (prior to day +100) but is also associated with an increased incidence of bacterial and fungal infections and with significant bone marrow toxicity (4, 13). Long-term use of GCV has raised concerns about the development of delayed CMV disease and the possibility of selecting GCV-resistant strains (11, 25). The second strategy, called preemptive or early treatment, is based on early identification of patients with active CMV blood infections using sensitive detection assays followed by antiviral treatment for various lengths of time.

A successful CMV pp65 antigenemia-guided preemptive strategy for allogeneic hematopoietic stem cell recipients was recently reported (5). In that study, 50 patients with hematologic malignancies received a transplant (not T cell depleted) from matched sibling donors. The subjects were monitored weekly for the presence of CMV antigens and DNA (COBAS AMPLICOR CMV MONITOR test; Roche Diagnostics, Laval, Canada) in polymorphonuclear leukocytes (PMNL) from initiation of the conditioning regimen until day +98 after transplantation. Among these 50 patients, 34 (68%) were treated with GCV (14 days of intravenous [i.v.] administration [5 mg/kg of body weight twice a day] followed by 14 days of oral administration [1,000 mg three times a day]) upon a positive pp65 antigenemia assay. Eight (23.5%) of these 34 patients received a second course of therapy based on the reemergence of CMV pp65 antigens in the blood. Only one patient (2%) enrolled in the study developed CMV disease despite a negative antigenemia test. To further support the use of such a preventive approach, we now report the results of genotypic markers of CMV resistance to GCV among the same cohort of patients.

Among samples from the 50 patients enrolled in our study, 13 from 10 patients were selected for genotypic analysis on the basis of either a positive PCR for CMV in PMNL after the patient had received at least 14 days of i.v. GCV during the first treatment course (5 samples) or a second positive test for CMV DNA in the blood within the first 98 days following transplantation (8 samples). In both cases, the last PCR-positive samples were examined for genotypic evidence of resistance. The subjects who had no positive PCR throughout the study or whose CMV DNA rapidly cleared within 14 days of the first GCV treatment were assumed not to be infected with a GCV-resistant virus. The samples were collected either after or during GCV therapy (mean, 31.6 days; median, 28.0 days; range, 14 to 56 days of cumulative GCV therapy). The mean viral DNA load as determined by the COBAS AMPLICOR CMV MONITOR test for those samples was 9.96 × 103 CMV DNA copies per 4 × 106 PMNL. The presence of various CMV UL97 mutations at codons 460, 520, 594, and 595 was assessed as previously described (12, 14). Briefly, two regions (nucleotides 1088 to 1587 and 1713 to 1830) of the CMV UL97 gene were amplified using a nested-PCR protocol. Amplicons were then digested separately with enzymes NlaIII and AluI (500-bp amplicon) as well as with HhaI, TaqI, andMseI (118-bp amplicon). Restriction patterns were then visualized on an 8% polyacrylamide gel stained with ethidium bromide.

Two samples from the same patient (collected after 28 and 35 days of cumulative GCV therapy) had a restriction pattern almost compatible with a Q520 mutation (Table 1). Upon sequencing, this specific restriction pattern was found to be caused by the presence of an Asn510Ser mutation, with a wild-type sequence at codon 520. All the other samples contained no CMV UL97 mutations at codons 460, 520, 594, and 595 by the restriction enzyme assay.

View this table:
  • View inline
  • View popup
Table 1.

CMV load and UL97 mutations in leukocytes of allogeneic blood transplant recipients with persistent or recurrent antigenemia despite GCV preemptive therapy

Over the past few years, some concerns have been raised regarding the selection of drug-resistant CMV strains in profoundly immunosuppressed transplant recipients. Indeed, the presence of such strains has been documented for solid organ transplant recipients (1-3, 17, 19-21, 26, 29) and BMT or PBSCT recipients (8, 9, 11, 16, 23-25, 27), although the exact frequency at which GCV resistance develops in those patients is not yet known. In theory, the use of a preemptive strategy which greatly reduces drug exposure (compared to the use of universal prophylaxis) should both decrease the incidence of drug resistance and limit antiviral-related toxicities in those patients. In addition, such an approach should also contribute to reduction of the rate of delayed CMV disease as a result of early reconstitution of a CMV-specific cellular immune response (18).

In our study, viral resistance to GCV was assessed by examining the presence of the most common UL97 mutations associated with GCV resistance directly in leukocytes of PBSCT recipients who had persistent CMV antigens or DNA in their blood after a minimum of 2 weeks of i.v. GCV or during a second viremic episode. Previous results from our group indicate that such a genotype-based screening assay is more sensitive than phenotypic (susceptibility) analyses in evaluating GCV resistance in human immunodeficiency virus-infected individuals (12). This technique also offers the advantage of detecting minor UL97 mutant subpopulations (at least 10%) mixed with wild-type strains (7) with an absolute sensitivity of 25 copies, as determined by testing for a plasmid containing the UL97 gene. The only UL97 mutation (S510) detected in our study has been previously reported to occur in susceptible CMV isolates (11) and is therefore not considered to be associated with GCV resistance. Thus, no UL97 mutations known to confer GCV resistance were identified in the 50 patients enrolled in our study (95% confidence interval, 0 to 6%). Although only 13 samples from 10 patients were tested, it could reasonably be assumed that the other patients did not harbor GCV-resistant strains in their blood since they consistently had negative PCR results or rapidly became PCR negative (within 2 weeks of therapy) and did not exhibit recurrent CMV DNA in their blood. These results suggest that the rate of emergence of viral resistance in the context of short courses of preemptive GCV therapy in allogeneic PBSCT recipients is very low. In the study by Erice et al. (11), all UL97 mutations conferring GCV resistance in blood isolates of BMT patients emerged after more than 2 months of cumulative GCV therapy preceded by acyclovir prophylaxis. In contrast, the length of drug exposure was significantly shorter in our patients (mean GCV exposure, 31.6 days; range, 14 to 56 days).

It is still possible that some other UL97 or UL54 (DNA polymerase) mutations conferring resistance to GCV were not detected by our screening assay. For example, UL97 mutations at codons 591 and 603 have been previously reported after BMT (9, 23). However, given the facts that UL97 mutations at codons 460, 520, 594, and 595 represent approximately 70% of UL97 mutations associated with GCV resistance (10) and that UL54 resistance mutations usually emerge after UL97 mutations (28), the probability of having missed a significant number of GCV resistance markers remains very low. These results are in agreement with the lack of selection of GCV-resistant CMV strains as assessed by phenotypic analyses of solid organ transplant recipients with CMV viremia who received brief courses of i.v. GCV (6) and of PBSCT recipients with rising CMV antigenemia while on preemptive GCV therapy (22). In addition, none of our patients developed clinical features suggestive of GCV resistance, such as the need for foscarnet therapy or the development of late CMV disease (19).

In conclusion, the absence of the most frequent genotypic markers for GCV resistance in this study, combined with the low incidence of CMV disease as previously reported (5), strengthens the safety and reliability of our preemptive GCV approach for PBSCT recipients.

FOOTNOTES

    • Received 23 April 2001.
    • Returned for modification 2 August 2001.
    • Accepted 27 August 2001.
  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Alain S.,
    2. Honderlick P.,
    3. Grenet D.,
    4. Stern M.,
    5. Vadam C.,
    6. Sanson-Le Pors M. J.,
    7. Mazeron M. C.
    Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 63 1997 1533 1536
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Baldanti F.,
    2. Simoncini L.,
    3. Sarasini A.,
    4. Zavattoni M.,
    5. Grossi P.,
    6. Revello M. G.,
    7. Gerna G.
    Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 66 1998 324 329
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Bienvenu B.,
    2. Thervet E.,
    3. Bedrossian J.,
    4. Scieux C.,
    5. Mazeron M. C.,
    6. Thouvenot D.,
    7. Legendre C.
    Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient. Transplantation 69 2000 182 184
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Boeckh M.,
    2. Gooley T. A.,
    3. Myerson D.,
    4. Cunningham T.,
    5. Schoch G.,
    6. Bowden R. A.
    Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88 1996 4063 4071
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Boivin G.,
    2. Bélanger R.,
    3. Delage R.,
    4. Béliveau C.,
    5. Demers C.,
    6. Goyette N.,
    7. Roy J.
    Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. J. Clin. Microbiol. 38 2000 4356 4360
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Boivin G.,
    2. Erice A.,
    3. Crane D. D.,
    4. Dunn D. L.,
    5. Balfour H. H. J.
    Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J. Infect. Dis. 168 1993 332 335
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Chou S.,
    2. Erice A.,
    3. Jordan M. C.,
    4. Vercellotti G. M.,
    5. Michels K. R.,
    6. Talarico C. L.,
    7. Stanat S. C.,
    8. Biron K. K.
    Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171 1995 576 583
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Drobyski W. R.,
    2. Knox K. K.,
    3. Carrigan D. R.,
    4. Ash R. C.
    Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. Transplantation 52 1991 155 157
    OpenUrlPubMed
  9. 9.↵
    1. Eckle T.,
    2. Prix L.,
    3. Jahn G.,
    4. Klingebiel T.,
    5. Handgretinger R.,
    6. Selle B.,
    7. Hamprecht K.
    Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96 2000 3286 3289
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Erice A.
    Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12 1999 286 297
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Erice A.,
    2. Borrell N.,
    3. Li W.,
    4. Miller W. J.,
    5. Balfour H. H. J.
    Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J. Infect. Dis. 178 1998 531 534
    OpenUrlCrossRef
  12. 12.↵
    1. Gilbert C.,
    2. Handfield J.,
    3. Toma E.,
    4. Lalonde R.,
    5. Bergeron M. G.,
    6. Boivin G.
    Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS 12 1998 125 129
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Goodrich J. M.,
    2. Bowden R. A.,
    3. Fisher L.,
    4. Keller C.,
    5. Schoch G.,
    6. Meyers J. D.
    Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118 1993 173 178
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Hanson M. N.,
    2. Preheim L. C.,
    3. Chou S.,
    4. Talarico C. L.,
    5. Biron K. K.,
    6. Erice A.
    Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob. Agents Chemother. 39 1995 1204 1205
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Hebart H.,
    2. Kanz L.,
    3. Jahn G.,
    4. Einsele H.
    Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Drugs 55 1998 59 72
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Knox K. K.,
    2. Drobyski W. R.,
    3. Carrigan D. R.
    Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 337 1991 1292 1293
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. Kruger R. M.,
    2. Shannon W. D.,
    3. Arens M. Q.,
    4. Lynch J. P.,
    5. Storch G. A.,
    6. Trulock E. P.
    The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 68 1999 1272 1279
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Li C. R.,
    2. Greenberg P. D.,
    3. Gilbert M. J.,
    4. Goodrich J. M.,
    5. Riddell S. R.
    Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83 1994 1971 1979
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Limaye A. P.,
    2. Corey L.,
    3. Koelle D. M.,
    4. Davis C. L.,
    5. Boeckh M.
    Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356 2000 645 649
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Lurain N. S.,
    2. Ammons H. C.,
    3. Kapell K. S.,
    4. Yeldandi V. V.,
    5. Garrity E. R.,
    6. O'Keefe J. P.
    Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 62 1996 497 502
    OpenUrlPubMedWeb of Science
  21. 21.↵
    1. Mendez J. C.,
    2. Sia I. G.,
    3. Tau K. R.,
    4. Espy M. J.,
    5. Smith T. F.,
    6. Chou S.,
    7. Paya C. V.
    Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. Transplantation 67 1999 755 757
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Nichols W. G.,
    2. Corey L.,
    3. Gooley T.,
    4. Drew W. L.,
    5. Miner R.,
    6. Huang M.,
    7. Davis C.,
    8. Boeckh M.
    Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 97 2001 867 874
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Prix L.,
    2. Hamprecht K.,
    3. Holzhuter B.,
    4. Handgretinger R.,
    5. Klingebiel T.,
    6. Jahn G.
    Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. J. Infect. Dis. 180 1999 491 495
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Razis E.,
    2. Cook P.,
    3. Mittelman A.,
    4. Ahmed T.
    Treatment of gancyclovir resistant cytomegalovirus with foscarnet: a report of two cases occurring after bone marrow transplantation. Leuk. Lymphoma 12 1994 477 480
    OpenUrlPubMed
  25. 25.↵
    1. Reusser P.,
    2. Cordonnier C.,
    3. Einsele H.,
    4. Engelhard D.,
    5. Link D.,
    6. Locasciulli A.,
    7. Ljungman P.
    European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 17 1996 813 817
    OpenUrlPubMedWeb of Science
  26. 26.↵
    1. Rosen H. R.,
    2. Benner K. G.,
    3. Flora K. D.,
    4. Rabkin J. M.,
    5. Orloff S. L.,
    6. Olyaei A.,
    7. Chou S.
    Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 63 1997 476 478
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Slavin M. A.,
    2. Bindra R. R.,
    3. Gleaves C. A.,
    4. Pettinger M. B.,
    5. Bowden R. A.
    Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob. Agents Chemother. 37 1993 1360 1363
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Smith I. L.,
    2. Cherrington J. M.,
    3. Jiles R. E.,
    4. Fuller M. D.,
    5. Freeman W. R.,
    6. Spector S. A.
    High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176 1997 69 77
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Tatarowicz W. A.,
    2. Lurain N. S.,
    3. Thompson K. D.
    A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J. Infect. Dis. 166 1992 904 907
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Lack of Emergence of Cytomegalovirus UL97 Mutations Conferring Ganciclovir (GCV) Resistance following Preemptive GCV Therapy in Allogeneic Stem Cell Transplant Recipients
C. Gilbert, J. Roy, R. Belanger, R. Delage, C. Beliveau, C. Demers, G. Boivin
Antimicrobial Agents and Chemotherapy Dec 2001, 45 (12) 3669-3671; DOI: 10.1128/AAC.45.12.3669-3671.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Lack of Emergence of Cytomegalovirus UL97 Mutations Conferring Ganciclovir (GCV) Resistance following Preemptive GCV Therapy in Allogeneic Stem Cell Transplant Recipients
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Lack of Emergence of Cytomegalovirus UL97 Mutations Conferring Ganciclovir (GCV) Resistance following Preemptive GCV Therapy in Allogeneic Stem Cell Transplant Recipients
C. Gilbert, J. Roy, R. Belanger, R. Delage, C. Beliveau, C. Demers, G. Boivin
Antimicrobial Agents and Chemotherapy Dec 2001, 45 (12) 3669-3671; DOI: 10.1128/AAC.45.12.3669-3671.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

antiviral agents
cytomegalovirus
Cytomegalovirus Infections
ganciclovir
hematopoietic stem cell transplantation

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596